$CRVS

Corvus Pharmaceuticals Inc

$CRVS

Corvus Pharmaceuticals Inc

Past 12mo:4mentions4voices

All voices2 calls since Jan 2026show all

Loading price chart…

Recent calls

2 calls

@acinvestorblogJan 20, 2026 · 9:01 PM

$CRVS offering Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Corvus. In addition, Corvus expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $22,500,000 of shares of common stock at the public offering price less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Open on X

@adamfeuersteinJan 20, 2026 · 12:04 PM

$CRVS Corvus pill shows promise in early-stage eczema trial 75% of participants treated with soquelitinib achieved EASI 75 after 8 weeks compared to 20% of placebo participants offered a placebo. https://t.co/XlOmX0GUZf

Open on X

About this stock

$CRVS has generated 4 mentions from 4 distinct FinTwit voices over the past 12 months, with the first mention appearing on November 27, 2025, and the most recent on January 20, 2026. The biotech category dominated discussion of Corvus Pharmaceuticals Inc., with voices including @acinvestorblog, @adamfeuerstein, @jacobplieth, and @photonbull each contributing one mention. The recent activity centered on two significant developments: a $150 million underwritten public offering of common stock and pre-funded warrants announced by the company, and clinical trial results showing promise for soquelitinib in early-stage eczema treatment.

AI-generated from tracked posts · updated Sep 5, 2026